TXG Stock Analysis: 10X Genomics | NASDAQ
Health Information Services | NASDAQ, USA | Market Cap: 4.716m USD | 12M Return: 227.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 114M
Qual. Beats: 0
Rev. Trend: 79.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 6.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
10x Genomics, Inc. (NASDAQ: TXG) is a life sciences tools company that develops and sells instruments, consumables, and software for the analysis of biological systems across the United States, the rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The companys product portfolio centers on three platforms: the Chromium single-cell analysis platform (including microfluidic chips, the Chromium X Series, and QuantumScale single cell RNA and methylation kits), the Visium spatial analysis platform (featuring HD gene expression assays and the Visium CytAssist instrument), and the Xenium Analyzer, which enables in situ detection of RNA targets in fresh frozen or FFPE tissue without conventional sequencing. It also offers a software suite, including Cell Ranger for scRNA-seq processing, Loupe Browser for single-cell and spatial data visualization, and Xenium Explorer for subcellular gene expression analysis.
The company serves academic, government, biopharmaceutical, biotechnology, and other research institutions. As a life sciences tools provider, it follows a razor-and-blade business model in which installed instruments drive recurring consumables revenue, a structure common across the sector. Founded in 2012 and headquartered in Pleasanton, California, the company was originally known as 10X Technologies, Inc. before adopting its current name in November 2014, and completed its initial public offering on September 12, 2019.
- Visium and Xenium spatial platforms drive consumables revenue growth
- Biotech funding weakness pressures biopharma instrument orders
- China revenue exposed to export controls and tariffs
| Net Income: -22.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 7.12 > 1.0 |
| NWC/Revenue: 87.06% < 20% (prev 75.53%; Δ 11.53% < -1%) |
| CFO/TA 0.13 > 3% & CFO 127.8m > Net Income -22.7m |
| Net Debt (-458.5m) to EBITDA (93.3m): -4.91 < 3 |
| Current Ratio: 5.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (128.3m) vs 12m ago 4.64% < -2% |
| Gross Margin: 69.60% > 18% (prev 68.36%; Δ 1.24% > 0.5%) |
| Asset Turnover: 66.57% > 50% (prev 69.15%; Δ -2.58% > 0%) |
| Interest Coverage Ratio: 0.71 > 6 (EBIT TTM 47.4m / Interest Expense TTM 66.6m) |
| A: 0.55 (Total Current Assets 669.7m - Total Current Liabilities 113.6m) / Total Assets 1.02b |
| B: -1.50 (Retained Earnings -1.52b / Total Assets 1.02b) |
| C: 0.05 (EBIT TTM 47.4m / Avg Total Assets 959.6m) |
| D: 4.04 (Book Value of Equity 814.3m / Total Liabilities 201.4m) |
| Altman-Z'' = 3.28 = A |
| DSRI: 1.04 (Receivables 56.1m/52.5m, Revenue 638.8m/624.7m) |
| GMI: 0.98 (GM 68.36% / 69.60%) |
| AQI: 2.71 (AQ_t 0.07 / AQ_t-1 0.02) |
| SGI: 1.02 (Revenue 638.8m / 624.7m) |
| TATA: -0.15 (NI -22.7m - CFO 127.8m) / TA 1.02b) |
| Beneish M = -1.99 (Cap -4..+1) = B |
As of July 06, 2026, the stock is trading at USD 39.01 with a total of 2,773,300 shares traded. Over the past week, the price has changed by +9.18%, over one month by +25.68%, over three months by +78.21% and over the past year by +227.27%.
Current recommended Stop Loss: 35.90 (which is 8% or 1.3 ATR below the current price).
10X Genomics has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold TXG.
- StrongBuy: 5
- Buy: 2
- Hold: 9
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 27.6 | -29.2% |
P/E Forward = 625.0
P/S = 7.3835
P/B = 5.7918
Revenue TTM = 638.8m USD
EBIT TTM = 47.4m USD
EBITDA TTM = 93.3m USD
Long Term Debt = 70.1m USD (estimated: total debt 81.4m - short term 11.3m)
Short Term Debt = 11.3m USD (from shortTermDebt, last quarter)
Debt = 81.4m USD (from shortLongTermDebtTotal, last quarter) (leases 81.4m already included)
Net Debt = -458.5m USD (calculated: Debt 81.4m - CCE 539.8m)
Enterprise Value = 4.26b USD (4.72b + Debt 81.4m - CCE 539.8m)
Interest Coverage Ratio = 0.71 (Ebit TTM 47.4m / Interest Expense TTM 66.6m)
EV/FCF = 34.85x (Enterprise Value 4.26b / FCF TTM 122.2m)
FCF Yield = 2.87% (FCF TTM 122.2m / Enterprise Value 4.26b)
FCF Margin = 19.13% (FCF TTM 122.2m / Revenue TTM 638.8m)
Net Margin = -3.55% (Net Income TTM -22.7m / Revenue TTM 638.8m)
Gross Margin = 69.60% ((Revenue TTM 638.8m - Cost of Revenue TTM 194.2m) / Revenue TTM)
Gross Margin QoQ = 70.39% (prev 68.09%)
Tobins Q-Ratio = 4.19 (Enterprise Value 4.26b / Total Assets 1.02b)
Interest Expense / Debt = 81.87% (Interest Expense 66.6m / Debt 81.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 37.4m (EBIT 47.4m * (1 - 21.00%))
Current Ratio = 5.90 (Total Current Assets 669.7m / Total Current Liabilities 113.6m)
Debt / Equity = 0.10 (Debt 81.4m / totalStockholderEquity, last quarter 814.3m)
Debt / EBITDA = -4.91 (Net Debt -458.5m / EBITDA 93.3m)
Debt / FCF = -3.75 (Net Debt -458.5m / FCF TTM 122.2m)
Total Stockholder Equity = 792.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.36% (Net Income -22.7m / Total Assets 1.02b)
RoE = -2.86% (Net Income TTM -22.7m / Total Stockholder Equity 792.3m)
RoCE = 5.50% (EBIT 47.4m / Capital Employed (Equity 792.3m + L.T.Debt 70.1m))
RoIC = 4.25% (NOPAT 37.4m / Invested Capital 881.6m)
WACC = 13.47% (E(4.72b)/V(4.80b) * Re(13.70%) + (debt cost/tax rate unavailable))
Discount Rate = 13.70% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 100.00 | Cagr: 3.57%
[DCF] Terminal Value 63.24% ; FCFF base≈91.1m ; Y1≈104.4m ; Y5≈153.6m
[DCF] Fair Price = 14.25 (EV 1.21b - Net Debt -458.5m = Equity 1.67b / Shares 116.9m; r=13.47% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.66 | # QB: 0
Revenue Correlation: 79.83 | Revenue CAGR: 3.39% | SUE: 0.35 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.02 | Chg30d=+61.43% | Revisions=+40% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.04 | Chg30d=N/A | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=0.00 | Chg30d=+100.00% | Revisions=+40% | GrowthEPS=-100.0% | GrowthRev=-4.5%
EPS next Year (2027-12-31): EPS=0.20 | Chg30d=+0.00% | Revisions=+40% | GrowthEPS=+0.0% | GrowthRev=+9.0%
[Analyst] Revisions Ratio: +55% (up=7, down=1)